Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30975296 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL477546 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL477567 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL477578 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL8193119 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL405975 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL477511 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL477608 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL22491606 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 | |
| SCHEMBL7120698 | 0.82 | LMNA (0.59) | ASAH1LMNACERT1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026026-A1 | HIGH THROUGHPUT IN VIVO SCREENING OF LIPID NANOPARTICLES | TRUSTEES OF TUFTS COLLEGE (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11666539-B2 | Synthetic lipid-like materials for brain delivery | TRUSTEES OF TUFTS COLLEGE (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666539-B2 | Synthetic lipid-like materials for brain delivery | NPC1L1, FABP7, LIPA | AOC3 2206/4885ASAH1 146/4885LMNA 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.